<DOC>
	<DOCNO>NCT01888432</DOCNO>
	<brief_summary>The purpose trial demonstrate efficacy safety everolimus combination reduce tacrolimus , compare tacrolimus control , live donor liver transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety Everolimus Liver Transplant Recipients Living Donor Liver Transplants</brief_title>
	<detailed_description>This study 24 month , multicenter study 280 living donor liver transplant patient Asia , Europe Canada . The study also long term extension Japan approximately 28 patient included evaluate long-term efficacy safety concentration-controlled everolimus regimen plus reduced tacrolimus compare standard tacrolimus recipient live donor liver transplant Japan participate CRAD001H2307 study .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion criterion : Written inform consent Subject age ≥18 year primary , orthotopic liver allograft , live donor Subject negative HIV Incusion criterion Randomization : Subject initated tacrolimusbased immunosuppressive regimen steroid immunosuppression Exclusion criterion : Subjects transplant acute liver failure HCV negativesubjects receive transplant HCV positive donor Subjects receive multiple solid organ ( include multiple liver lobes/segments ) islet cell tissue transplant , previously receive organ tissue transplant . Subjects receive ABO incompatible allograft . MELDscore &gt; 35 within 1 month prior transplantation . Use immunosuppressive antibody induction agent specify protocol . History malignancy organ system ( except hepatocellular carcinoma localize basal cell carcinoma skin ) Hepatocellular carcinoma extrahepatic spread macrovascular invasion Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 2 week last dose study medication History hypersensitivity study drug drug similar chemical class , excipients Exclusion criterion Randomization : Any posttransplant history thrombosis , occlusion stent placement major hepatic artery , hepatic vein , portal vein inferior vena cava time runin period prior randomization . Subjects confirm spot urine protein/creatinine ratio indicate ≥ 1.0 g/24 hr proteinuria Subjects severe hypercholesterolemia ( &gt; 350 mg/dL ; &gt; 9.1 mmol/L ) hypertriglyceridemia ( &gt; 500 mg/dL ; &gt; 5.6 mmol/L ) randomization . Subjects platelet count &lt; 30,000/mm3 . Subjects absolute neutrophil count &lt; 1,000/mm³ white blood cell count &lt; 2,000/mm³ . Subjects systemic infection require active use IV antibiotic . Subjects require life support measure ventilation , dialysis , vasopressor agent . Subjects require renal replacement therapy within 7 day prior randomization . Subjects detectable HBV DNA time randomization Subjects meeting follow criterion acute rejection run period : Any acute rejection week prior randomization . 2 treat acute rejection . Any rejection require antibody treatment . Any severe cellular ( and/or humoral ) rejection . Other protocoldefined inclusion/exclusion criterion may apply . Long term extension patient Japan : Inclusion criterion Written inform consent must obtain extension specific assessment perform . Ability willingness adhere study regimen . Completed Month 24 visit core study continuously treat assigned regimen . Exclusion criterion : Use medication prohibit study protocol Month 24 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . History hypersensitivity study drug drug similar chemical class , excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>liver transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>reduce calcineuron inhibitor</keyword>
	<keyword>renal function</keyword>
	<keyword>live donor</keyword>
	<keyword>RAD001H2307</keyword>
	<keyword>RAD001H</keyword>
</DOC>